Page last updated: 2024-12-06
atamestane
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
atamestane: aromatase inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 57050 |
| CHEMBL ID | 2105987 |
| SCHEMBL ID | 59128 |
| MeSH ID | M0140089 |
Synonyms (26)
| Synonym |
|---|
| sh-489 |
| biomed-777 |
| atamestane |
| atamestano [spanish] |
| atamestane [inn] |
| atamestanum [latin] |
| 1-methyl-1,4-androstadiene-3,17-dione |
| androsta-1,4-diene-3,17-dione, 1-methyl- |
| ccris 6528 |
| 1-methylandrosta-1,4-diene-3,17-dione |
| (8r,9s,10s,13s,14s)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione |
| 62ga3k28b6 , |
| atamestanum |
| 96301-34-7 |
| atamestano |
| unii-62ga3k28b6 |
| CHEMBL2105987 |
| SCHEMBL59128 |
| atamestane [who-dd] |
| PEPMWUSGRKINHX-TXTPUJOMSA-N |
| 1-methyl-androsta-1,4-diene-3,17-dione |
| 1-methyl-androsta-1,4 -diene-3,17-dione |
| DB12194 |
| Q4812727 |
| (8r,9s,10s,13s,14s)-1,10,13-trimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3h-cyclopenta[a]phenanthrene-3,17(6h)-dione |
| DTXSID30869268 |
Research Excerpts
Overview
Atamestane is a potent competitive inhibitor of estrogen biosynthesis (aromatase) in several species, in vitro and in vivo. It has no endocrine side effects.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Atamestane is a new, competitive, and irreversible inhibitor of estrogen biosynthesis. " | ( Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia. el Etreby, MF; Habenicht, UF; Henderson, D; Nishino, Y, ) | 3.02 |
| "Atamestane is a potent competitive inhibitor of estrogen biosynthesis (aromatase) in several species, in vitro and in vivo, and has no endocrine side effects. " | ( Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors. el Etreby, MF; Michna, H; Nishino, Y; Schneider, MR, 1989) | 1.94 |
Actions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Atamestane caused an increase in LH levels, while no effect was observed with oral exemestane." | ( Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours. di Salle, E; Giudici, D; Ornati, G; Panzeri, A; Zaccheo, T, 1991) | 1.23 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with atamestane (10 micromol/l) determined a strong inhibition of basal aromatase activity in both types of cells; however, its effect was markedly more pronounced in granulosa cells from normal ovary than in granulosa cells from polycystic ovaries (PCO; P < 0.01)." | ( Further evidence of increased aromatase activity in granulosa luteal cells from polycystic ovary. Andreani, CL; Caruso, A; Cento, R; Lanzone, A; Lazzarin, N; Mancuso, S; Pierro, E, 1997) | 0.64 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (37)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 12 (32.43) | 18.7374 |
| 1990's | 19 (51.35) | 18.2507 |
| 2000's | 6 (16.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 25.12
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.12) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (17.07%) | 5.53% |
| Reviews | 7 (17.07%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 27 (65.85%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (4)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [NCT00097344] | Phase 3 | 842 participants | Interventional | 2004-12-31 | Terminated(stopped due to Identical study Biomed 777-CLP-029 did not meet superiority endpoint) | ||
| Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [NCT00267553] | Phase 3 | 200 participants | Interventional | 2005-11-30 | Terminated(stopped due to This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint) | ||
| Phase III Study of Atamestane Plus Toremifene in Metastatic Breast Cancer [NCT00010322] | Phase 3 | 0 participants | Interventional | 2000-10-31 | Terminated(stopped due to Withdrawn due to change in standard of care - new protocol required) | ||
| [NCT00044291] | Phase 3 | 865 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||